RIPK3作为预测肝硬化急性失代偿患者结局的新型生物标志物的识别与验证
本研究在200例肝硬化急性失代偿(AD)患者(其中153例合并慢加急性肝衰竭ACLF)中检测基线及第7天的细胞死亡标志物,发现RIPK3与多器官衰竭及死亡独立相关。将RIPK3>2.261倍正常值上限(ULN)纳入包含CLIF-C OF及白细胞增多/减少的死亡预测模型,在推导队列中AUC为0.839,并在三个独立队列中验证。
要点
- RIPK3水平随肝硬化急性失代偿疾病严重程度升高,与多器官衰竭尤其肝、肾衰竭强相关(p<0.05)。
- 基线RIPK3升高独立关联疾病进展(aOR 4.85)和死亡(aOR 4.74),动态下降见于病情改善存活者。
- 含RIPK3>2.261×ULN的预测模型在推导队列AUC 0.839,两个验证队列AUC 0.752和0.794。
核心结论
- RIPK3相关的细胞死亡是肝硬化急性失代偿/慢加急性肝衰竭中器官衰竭和死亡的关键驱动因素。
- 将血浆RIPK3纳入预后模型可增强风险分层,并可能指导个体化使用靶向细胞死亡的治疗。
研究设计与样本
- 推导队列纳入200例急性失代偿患者(其中153例合并ACLF),检测基线及第7天血浆细胞角蛋白-18(M30、M65)、RIPK3、MLKL及gasdermin D。
- 建立死亡预测模型并在三个独立队列(n=106、150、100)中验证。
- 第四队列(n=21)的肝活检组织进行细胞死亡标志物染色。
主要发现
- 细胞死亡标志物随疾病严重程度升高,RIPK3与多器官衰竭尤其肝、肾衰竭关联最强(p<0.05)。
- 基线RIPK3较高独立关联疾病进展(校正OR 4.85;95%CI 2.36-9.94;p<0.001)和死亡(校正OR 4.74;95%CI 2.38-9.44;p<0.001)。
- RIPK3升高与临床病程恶化及死亡相关,病情改善存活者中RIPK3下降(p<0.001)。
- 含RIPK3>2.261×ULN、CLIF-C OF及白细胞增多/减少的死亡预测模型在推导队列AUC为0.839,两个验证队列AUC分别为0.752和0.794。
- 第三验证队列证实时间演变(AUC 0.796);第四队列中ACLF患者肝组织RIPK1表达增加并与死亡率相关。
关键数值与推荐
- RIPK3>2.261×ULN被纳入死亡预测模型,联合CLIF-C OF及白细胞增多/减少。
- 推导队列模型AUC 0.839;两个独立验证队列AUC 0.752和0.794;第三验证队列AUC 0.796。
临床怎么用
- 对肝硬化急性失代偿患者可检测血浆RIPK3,结合CLIF-C OF及白细胞计数进行死亡风险分层。
- RIPK3动态变化可用于监测临床病程,下降提示病情改善和存活。
- RIPK3升高可能识别适合靶向坏死性凋亡治疗的个体化人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with cirrhosis who experience acute decompensation (AD) or acute-on-chronic liver failure (ACLF), non-apoptotic forms of cell death correlate with disease severity and represent potential therapeutic targets. This study evaluated the role of cell death markers in predicting organ dysfunction, clinical course, and outcomes in AD/ACLF. METHODS: A derivation cohort of 200 individuals with AD (153 with ACLF) was recruited. Plasma cytokeratin-18 (M30: apoptosis; M65: total cell death), RIPK3 and MLKL (necroptosis), and gasdermin D (pyroptosis) were measured at baseline and day 7. A mortality prediction model was developed and validated in three independent cohorts (n = 106, 150, and 100). Liver biopsies from a fourth AD/ACLF cohort (n = 21) were stained for cell death markers. RESULTS: Cell death markers increased with disease severity, with RIPK3 levels showing the strongest association with multi-organ failure, particularly hepatic and renal (p <0.05 for each). Higher baseline RIPK3 was independently associated with disease progression (adjusted odds ratio 4.85; 95% CI 2.36-9.94; p <0.001) and mortality (adjusted odds ratio 4.74; 95% CI 2.38-9.44; p <0.001). Increasing RIPK3 correlated with worsening clinical course and death, while reductions were observed in those who improved and survived (p <0.001). A mortality prediction model incorporating RIPK3 >2.261x ULN, CLIF-C OF, and leukocytosis/leukopenia demonstrated high accuracy (AUC: 0.839) in the derivation cohort and was validated in two independent cohorts (AUC: 0.752 and 0.794, respectively). Temporal evolution was confirmed in the third validation cohort (AUC: 0.796). Hepatic RIPK1 expression was increased in individuals with ACLF and was associated with mortality in the fourth cohort. CONCLUSIONS: RIPK3-associated cell death is a key driver of organ failure and mortality in AD/ACLF. Incorporating plasma RIPK3 into prognostic models enhances risk stratification and may guide personalized use of cell death-targeted therapies in individuals with AD/ACLF. IMPACT AND IMPLICATIONS: Our study underscores the pivotal role of RIPK3 as a biomarker in acute decompensation (AD) and acute-on-chronic liver failure (ACLF), linking its elevated levels with disease progression, organ dysfunction, and mortality. In liver biopsies, hepatic RIPK1 expression was significantly higher in ACLF than AD and correlated with disease severity and mortality, supporting the hepatic origin of RIPK1 and RIPK3. Through the integration of RIPK3 into predictive models, we provide a path towards personalized therapeutic strategies for AD by targeting necroptosis. This approach has the potential to revolutionize risk stratification, enhance clinical decision-making, and improve outcomes for these high-risk patients.
引用
- Verma N, Garg P, Kaur P, et al. Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis. J Hepatol. 2025. PMID: 40812668. doi:10.1016/j.jhep.2025.07.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。